Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyro™ (repotrectinib) for ...
TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, even in later treatment lines. The study involved 293 patients, ...
The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...
– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback